Video

Dr. Slotky on Evolving Treatment with Stem Cell Transplants in Multiple Myeloma

Ronit Slotky, PhD, director, Cell Therapies Manufacturing Facility, Hackensack University Medical Center, discusses the evolving treatment landscape of stem cell transplants in multiple myeloma.

Stem cell transplants have been part of the treatment paradigm for patients with multiple myeloma for more than 20 years, Slotky says. Though other treatment regimens within multiple myeloma have emerged in recent years, the use of stem cell transplants has remained largely unchanged, Slotky explains.

Since the use of stem cells transplants has remained consistent since their inception, the improvement of other treatment options in multiple myeloma has benefited patient outcomes with a lower incidence of adverse effects, Slotky continues. These regimens now being given have allowed patients to live for a long time following diagnosis, Slotky concludes.

Related Videos
Dr Sullivan on RP1 Plus Nivolumab in Anti–PD-1–Refractory Melanoma
Neeta Somaiah, MD
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
4 experts are featured in this series.